Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)
Adam Gibb, Sarah J Pirrie, Kim Linton, Kathryn Paterson, Andrew J Davies, Graham P Collins, Tobias Menne, Pamela McKay, Paul A Fields, Fiona M Miall, Eszter Nagy, Keith Wheatley, Rachel Reed, Ivona Baricevic-Jones, Sally Barrington, J Radford
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)'. Together they form a unique fingerprint.